Renal denervation in refractory hypertension: joint statement of the German hypertension league DHL eV and the German societies of cardiology, angiology, nephrology and radiology

Vonend O, Boehm M, Eckert S, Hausberg M, Rittger H, Rump LC, Schmieder R, Schulte KL, Schunkert H, Uder M, Veelken R, Vorwerk D, Weil J, Wenzel U, Mahfoud F (2015)


Publication Type: Journal article

Publication year: 2015

Journal

Publisher: Georg Thieme Verlag

Book Volume: 140

Pages Range: 363

Journal Issue: 5

DOI: 10.1055/s-0041-100835

Abstract

Arterial hypertension is a major risk factor for cardiovascular mortality and remains insufficiently controlled in Germany. The sham controlled Symplicity HTN-3 trial did meet its primary safety endpoint but failed to meet its primary efficacy endpoint. Renal denervation can not replace established, well-proven therapies. It can only be used in selected truly resistant hypertensive patients as an additive approach and should be performed by specialized centers only. Randomized controlled trials are needed to further evaluate renal denervation.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Vonend, O., Boehm, M., Eckert, S., Hausberg, M., Rittger, H., Rump, L.-C.,... Mahfoud, F. (2015). Renal denervation in refractory hypertension: joint statement of the German hypertension league DHL eV and the German societies of cardiology, angiology, nephrology and radiology. Deutsche Medizinische Wochenschrift, 140(5), 363. https://doi.org/10.1055/s-0041-100835

MLA:

Vonend, Oliver, et al. "Renal denervation in refractory hypertension: joint statement of the German hypertension league DHL eV and the German societies of cardiology, angiology, nephrology and radiology." Deutsche Medizinische Wochenschrift 140.5 (2015): 363.

BibTeX: Download